Michael Okunewitch
Stock Analyst at Maxim Group
(0.54)
# 4,096
Out of 5,182 analysts
27
Total ratings
24%
Success rate
-17.59%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBLG FibroBiologics | Downgrades: Hold | n/a | $1.24 | - | 2 | May 4, 2026 | |
| VNRX VolitionRx | Downgrades: Hold | n/a | $2.42 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $0.94 | +965.64% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $0.92 | +554.38% | 3 | Sep 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $0.39 | +8,972.06% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.25 | +182.35% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.69 | +1,556.80% | 2 | Feb 20, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.46 | +106.19% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.46 | +173.97% | 1 | Oct 15, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.87 | +589.73% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.68 | +1,659.01% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.12 | +1,032.08% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.49 | +622.89% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $1.08 | +187,400.00% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.50 | +42.86% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.25 | +2,300.96% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.11 | +508.27% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.69 | +14,468.76% | 1 | Nov 30, 2021 |
FibroBiologics
May 4, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.24
Upside: -
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.42
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $0.94
Upside: +965.64%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $0.92
Upside: +554.38%
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $0.39
Upside: +8,972.06%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.25
Upside: +182.35%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.69
Upside: +1,556.80%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.46
Upside: +106.19%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.46
Upside: +173.97%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.87
Upside: +589.73%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.68
Upside: +1,659.01%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $2.12
Upside: +1,032.08%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.49
Upside: +622.89%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $1.08
Upside: +187,400.00%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.50
Upside: +42.86%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $0.25
Upside: +2,300.96%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $4.11
Upside: +508.27%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.69
Upside: +14,468.76%